65,437 trials
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] — 41.2 percentage of participants
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 11.0 percentage of participants
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Response Per RECIST Criteria — 0 participants
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
Recurrent Urinary Tract Infection
Primary: Days — 200; 52.7 days
Postmenopausal Symptoms
Primary: Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12. — 11.79; 11.65; -4.71; -3.36 Hot flash per day — p=<0.0001
Leukemia
Primary: Recommended Phase 2 Dose (RP2D) of BMS-833923 Plus Dasatinib in Chronic Myeloid Leukemia-Chronic Phase — 50 mg
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
Fabry Disease
Primary: Number of Serious Adverse Event (SAE) — 0 events
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 19.0; 30.4; 38.1 percentage of participants — p=0.0001
Phobic Disorders · Anxiety · Social Phobia
Primary: Clinical Global Improvement (CGI-S) Scale — 4.167; 3.833 units on a scale
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 18.3; 28.4; 40.7 percentage of participants — p=<0.0001
Psoriasis
Primary: Percentage of Participants With Greater Than or Equal to 75 Percent (%) Improvement in Psoriasis Area and Severity Index (PASI) Score — 6.5; 59.4; 67.7 Percentage of…
Prostate Cancer
Primary: PSA Response Rate — 15.4 percentage of participants